The Mucin 1 pipeline drugs market research report outlays comprehensive information on the Mucin 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mucin 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Non Malignant Disorders, Undisclosed, and Infectious Disease which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Adenomas, Unspecified, and Coronavirus Disease 2019 (COVID-19). It also reviews key players involved in Mucin 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Mucin 1 pipeline targets constitutes close to 70 molecules. Out of which, approximately 55 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 9, 6, 1, 27, and 12 respectively. Similarly, the universities portfolio in Phase II, Phase I, Phase 0, Preclinical, and Discovery comprises 5, 3, 2, 3, and 2 molecule.
Mucin 1 overview
Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response.
For a complete picture of Mucin 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
